U.S. Legislative Response to Heparin Crisis Begins to Take Shape
This article was originally published in PharmAsia News
Executive Summary
The broad outlines of the timing and scope of a U.S. legislative response to the global pharmaceutical supply chain crisis are taking shape
You may also be interested in...
User Fee Bill Puts Industry, U.S. FDA to Work On Global Supply Chain Risks
The user fee legislation U.S. Congress approved June 26 makes quality risk management a GMP requirement, further pressuring pharmaceutical manufacturers to make sure they are protecting their global supply chains.
U.S. FDA Warning Letter To Sichuan Pharma Only Tip Of The Iceberg For China State-Owned Company
WASHINGTON and SHANGHAI - U.S. FDA issued Sichuan Pharmaceutical Co., Ltd. a warning letter Sept. 9 for significant deviations from current good manufacturing practices in the manufacture of active pharmaceutical ingredients. The warning letter adds more woes to the troubled China state-owned enterprise, and the Chengdu government is looking for a basement price to unload the company
U.S. FDA Warning Letter To Sichuan Pharma Only Tip Of The Iceberg For China State-Owned Company
WASHINGTON and SHANGHAI - U.S. FDA issued Sichuan Pharmaceutical Co., Ltd. a warning letter Sept. 9 for significant deviations from current good manufacturing practices in the manufacture of active pharmaceutical ingredients. The warning letter adds more woes to the troubled China state-owned enterprise, and the Chengdu government is looking for a basement price to unload the company